The third batch of collections will come to an end, and the west is not the market or will be reconstructed accordingly

The results of the third batch of collection selection has been announced for more than half a month, the collection of a total of 189 enterprises to participate in the selection of 125 enterprises, 191 products to be selected, the average price reduction of the selected products 53%, the highest reduction of 95%.
Among them, from the results of the bid, Qilu became one of the big winners, the proposed bid of 8 varieties, the largest number, followed by Yangzijiang and Howson Pharmaceuticals, respectively, 7 and 5, Haizheng, Hengrui and Colum Pharmaceuticals are 4, the competition between pharmaceutical companies than the first two batches more intense.
this, Qilu Pharmaceuticals'acid sidna tablets were quoted at 2.08 yuan per tablet, a decrease of 92%, according to the National Drug Centralized Procurement Document (Purchase Document No. GY-YD2020-1) In 12.1 "units comparable price≤ with the lowest varieties" units can be compared 1.8 times" to become the only exclusive collection of winning varieties, will get 50% of the national procurement volume.
industry estimates that october may enter the full implementation phase.
And now the largest supplier of this variety in China Baiyunshan responded to the bid for The Jingo, Baiyunshan official said, "the product is mainly sold in the chain of pharmacies and other terminals, last year its sales in public hospitals accounted for only 0.01% of the annual sales."
, it is not expected that the loss of tenders will have a significant impact on the company's operations.
future, the company will actively promote the product in other channels of sales promotion and market development efforts to reduce the impact of the failed bid.
."
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
according to the Results Table (GY-YD2020-1) of the National Drug Central Procurement, Qilu Pharmaceuticals is theoretically expected to sell less than 5 million tablets in the next year in medical institutions. Less than 10% of Baiyunshan Jingo's 2019 sales, based on the selected purchase price, its market sales are less than 20 million yuan, but its actual market will be much larger, and its impact will be deeper.
according to the collection of relevant documents specifically, in the next year the hospital terminal collection of 25mg, 50mg and 100mg a total of 917.24 million pieces, of which 25mg of 177 77,000 tablets, 50mg for 5.1845m, 100mg for 2.2092 million tablets, corresponding to the exclusive winning bid to obtain 50% of the base of procurement to It is calculated that Qilu will be able to obtain 989.4 million tablets, 2.5923 million tablets and 1.1046 million tablets respectively in the coming year; mg and 100mg single-piece selection price is 2.082 yuan, 3.609 yuan and 6.33 yuan, respectively, the corresponding market sales of 18.1992 million yuan.
But in practice, it can gain market share far more than that, because of the huge drop in the price of medical institutions, the original purchase of drugs in pharmacies will be directed to the fixed patients to medical institutions, medical institutions are likely to be far more than the actual implementation of procurement volume than originally planned.
In accordance with the Results Table of the National Drug Centralized Procurement (GY-YD2020-1), "On the basis of giving priority to the use of selected drugs in the centralized procurement of this drug, the remaining dosing may be used in accordance with the relevant provisions of the local centralized procurement management of drugs, and the appropriate amount of other drugs at the same price."
" clause, it seems that the rest of the manufacturers still have a chance to share the remaining 50% of the market, but it is not.
based on the end-market data of Minet medical institutions, Pfizer, a non-original research manufacturer, has a basic monopoly on the market, with sales of nearly 120 million yuan and a market share of more than 96% in 2019.
qilu's price advantage is much greater than the rest of the manufacturers, so the rest of the manufacturers, especially the original manufacturers are also difficult to significantly reduce prices to destroy its entire price system.
. Qilu's sharp price reduction, what is the intention? Qilu as the latest approved enterprises in the market, in the face of the old drug company Baiyunshan Jingo for many years to cultivate the market, if close to the price in the market competition, in the short term will certainly be difficult to open the market quickly.
According to the current retail market manufacturers in the general competitive landscape, in 2019 in China's urban retail pharmacy terminal sales of more than 2.3 billion yuan, the current 2019 domestic Western Tiana non-market share of the top three enterprises are Baiyunshan Jingo 48.1%, Pfizer 46.9%, Yabang Epson 3.7%, and later some listed Changshan Pharmaceuticals, Chengdu, the basic market.
, Qilu Pharmaceuticals is expected to quickly open up market visibility and share the retail market with price advantage after winning the bid at a low price.
there are many places to make the pharmacy into the collection of voices, and the voice is getting higher and higher, the future of medical terminal channels and retail terminal linkage is difficult to avoid.
To take Guangdong Province as an example, according to the data released by the Guangdong Pharmaceutical Trading Center on the non-pre-purchase volume of the third batch of Guotsexidana, the 25mg dose of the hospital was reported at 2000 tablets, and the pharmacy was reported at 1522926 tablets, 761 times that of the hospital; The mg dose of the hospital reported 19960 tablets, the pharmacy reported 3708630 tablets, 185 times that of the hospital, the 100 mg dose of the hospital reported 83325 tablets, the pharmacy reported 959475, 11 times the hospital.
Note: Guangdong Province, the third batch of non-pre-procurement volume table.
according to the contract of purchase and sale with volume, the fixed-point retail pharmacy of medical insurance should complete the contract amount during the contract period.
also indicates that there will be 28,000 pharmacies in Guangdong selling Chilu-produced Sidana non-, and to complete the contract usage during the contract period.
, Qilu's low-cost exclusive selection can also quickly open up the pharmacy market.
does Qilu make money? When the results of the previous two volume purchases were announced, many media thought that some of the drugs with huge drops were "losing money and drinking", winning the market but losing money, qilu would be so? Let's assume that the 50mg-sized Siddana, which is sold in the mainstream of the market, is used as an example to calculate the bill.
In China's pharmaceutical market industry rankings, Qilu Pharmaceuticals and Baiyunshan Pharmaceuticals are the higher ranked enterprises, assuming that the two in the variety of gross margin level, marketing management capacity is not much different.
according to data disclosed in Baiyunshan's annual report, sales in 2019 were 61.76 million tablets and sales revenue was 753 million yuan, due to the sale of products in 25mg, 50mg and 100mg sizes, and 50mg mainly, 25mg small specifications and 100mg large specification ratio hedging, assuming that the average factory price of each piece is about 12.19 yuan, the corresponding production cost is 12.19 x (1-90.65%) ≈1.14 yuan.
Assuming that the production costs of Qilu Pharmaceuticals are corresponding at 1.14 yuan, the gross margin of 50mg Sidna is 3.609 yuan per tablet, and even at a more conservative gross margin of 60%, the gross margin per tablet is more than 2.1 yuan.
and the purchase of drugs with volume basically no need for more sales cost-sharing, excluding a small amount of management costs and tax costs of enterprises is a net profit.
can be seen, Qilu this low-cost exclusive bid Xidinga is not "lose money to earn a drink" action.
does this have on the non-variety market in The West? At present, the market share and share of the top two are enterprises for Baiyunshan's Jingo and the original research drug Pfizer's Wan Aico.
although Baiyunshan officials said the impact is small, in the end the impact is small, can only be verified by the future market.
, it is inevitable that prices will be reduced in the markets at various terminals in the future.
prescription drugs, in theory should generally have a greater market share in the medical institution terminal, but its sales in the medical institution terminal market is less than one-tenth of the size of the retail terminal.
for the end-market of medical institutions, due to its ultra-low price advantage, its market sales volume is expected to expand rapidly in the future, narrowing the gap between its size and the pharmacy market.
for the general pharmacy terminal, this kind of product is the pharmacy profit higher sales of better merchandise category, will not easily give up this profit, the future price exchange is more likely.
This kind of products and some low-cost slow disease products to "guide" the purpose of the user is different, such products brand or trademark has a certain degree of partition, but earlier into the Chinese market of the original research brand Wan Aico and the domestic first imitation enterprise Jingo has accumulated a large number of stable customer base.
for the production of this variety on the market, the future overall price level down is inevitable.
specifically, relative to the actual market price of Wan Aico Qilu Pharmaceuticals Xidana non-selected price reduction of more than 90%, relative to Baiyunshan's Jingo is about 85%.
, more and more retail pharmacies are participating in the national collection, so the future of the product in the retail channels to reduce prices or price wars are inevitable.
, the price reconstruction of Zilu Pharmaceuticals' Sidna non-prying products throughout the market is inevitable.
As a leading enterprise in the market, Baiyunshan, Jingo has become the third largest sales revenue products in its Great Southern Pharmaceuticals sector, after the enterprise's cephalosporineand cephalosporine , but its gross margin level is much higher than the first two, calling it the most profitable varieties of the enterprise is not too much.
: The data comes from Baiyunshan's 2019 annual report.
, however, with this "service", as the third batch of volume procurement enters the implementation phase, the price level drops, the gross margin of West Tynafei may face challenges in the future.
title: the third batch of national varieties, the market changes